HD-OPM Archive
Topics › Infections & vaccines

TOGETHER metformin trial retracted; COVID-OUT and ACTIV-6 still support metformin

Louis Nervegna · Mar 08, 2026 · ♥ 5 reactions · 4 comments · original Facebook post
Infections & vaccinesInsulin resistance & diabetesHow to read research
AI summary & key facts

The TOGETHER trial of metformin for early COVID-19 was retracted by its authors in October 2025 after an analysis error led to premature stopping. Louis notes that two other large randomized trials, COVID-OUT and ACTIV-6, independently showed metformin lowers long-COVID risk, and hopes for a corrected re-publication.

The TOGETHER trial, one of the multiple randomized trials that demonstrated a protective effect of metformin against long covid, was retracted from publication by its authors in October 2025.

It looks like there was an unintentional error in the data analysis that led to the trial being stopped early (successfully). After reanalysis, the trial should not have been stopped, as primary endpoints were not met early.

It is important to point out that two other large randomized trials, COVID-OUT and ACTIV-6, have both independently demonstrated that metformin lowers the risk of long covid by a substantial amount. These results have never been called into question.

This is a sad situation. There appears to have been a trend towards benefit in TOGETHER, but stopping early has prevented the authors from determining the true result. Hopefully, we will see a re-publication with updated analysis and findings that discuss this trial in the context of the others that have been published.

In the meantime, results from the successful COVID-OUT and ACTIV-6 trials were published here:

PaperThe Lancet articlethelancet.com Paper · 2025Metformin on the Presence of COVID-19 Symptoms Over 6 Months: The ACTIV-6 Randomized Clinical TrialBackground The effect of metformin on preventing long-term COVID-19 symptoms among low-risk adults has not been studied. The objective of this study was to Assess metformin compared with placebo during acute SARS-CoV-2 infection on the presence of COVID-19 symptoms 180 days later. Methods The ACTIV-6 platform evaluated repurposed medications for mild to moderate COVID-19. Between September 19, 2023 and May 1, 2024,…medrxiv.org

The results of COVID-OUT and ACTIV-6 were discussed in the following posts:

↪ COVID-OUT: early metformin cut long Covid risk by 42% in a large randomized trial

↪ Metformin cuts long COVID risk in two large randomized trials, COVID-OUT and ACTIV-6

↪ Starting metformin at acute COVID infection lowers long COVID risk in two large RCTs

↪ Metformin cut SARS-CoV-2 viral load 3.6-fold in the COVID-OUT randomized trial

#merforminHD #covidHD #metformincovidHD #togetherHD #covidoutHD #activ6HD #longcovidHD

PaperThe Lancet articleThis article has been retracted: please see Elsevier Policy on Article Withdrawal ().In December 2021, The Lancet Regional Health-Americas published the results of the platform randomized TOGETHER trial, which evaluated the effect of early tr...thelancet.com

Research cited

← newer: Sildenafil users had lower Alzheimer's risk in real-world daolder: Flu and respiratory infections temporarily raise heart attac →